LEAVES BIO

Find Freedom From Weed

Important Facts about Clinical Trials

Here are some key facts about clinical trials:

Cost-Free Participation: Clinical trials are free for participants; all expenses are covered by sponsors (like pharmaceutical companies or universities).
Eligibility Requirements: Not everyone qualifies to participate in a clinical trial. For example, some trials may require participants to be under 75 years old or to meet specific health criteria, such as not having anemia.
Informed Consent: Before joining, doctors and nurses provide detailed information about the trial and require participants to sign an informed consent form.
Right to Withdraw: Participants can leave a clinical trial at any time without penalties.
Safety Oversight: While benefits are not guaranteed, regulatory agencies (like the FDA) ensure participant safety by closely reviewing trial designs, including minimizing procedures like blood draws.

Available Clinical Trials for Cannabis Use Disorder

We only list clinical trials that are actively recruiting for new patients. For completed clinical trials, please refer to clinicaltrials.gov for more information.

1. Psilocybin-assisted Treatment for Cannabis Use Disorder

This pilot study will evaluate the therapeutic potential of psilocybin (magic mushroom) in people with Cannabis Use Disorder (CUD).

Study ID

ClinicalTrials.gov ID NCT06660381
Sponsor Johns Hopkins University
Last Update Posted 2024-10-28
Link to the study.

Basic information about this study

This study will start around Nov 2024.
About 12 subjects will be enrolled.
In this study, participants will complete a 12-week course of study treatment including two psilocybin sessions (at week 5 and week 7) with psychological support (cognitive behavioral therapy), and be followed up at 3 months after 1st psilocybin session, and 6 months after 1st psilocybin session.
The goal of this study is to test if psilocybin plus therapy can reduce participants’ marijuana usage.

Who can participate in this study?

≥ 18 years of age.
Diagnosed with Cannabis Use Disorder per DSM-5 criteria

Who can NOT participate in this study?

Under weight (body weight < 50 kg, which is 110 lb)
Medically Unstable (heart issue, kidney issue, liver issue, abnormal lab values, etc.)
Family History of Schizophrenia, Bipolar Disorder, or Psychotic Disorder.
Medical History of Insulin-dependent diabetes, dementia, seizures, or immunosuppressive illness.
Not fluent in English
Currently pregnant or nursing
Suicidal ideation or behavior

Leaves Bio's Comments about this study

It’s exciting to see that the prestigious Johns Hopkins University is researching cannabis use disorder.
With only 12 slots available for this study, it’s important to act quickly if you’re interested.
The study is based in Baltimore, Maryland (5510 Nathan Shock Drive, Baltimore, MD 21224), so those living farther away may have a lower chance of being selected.
Psychedelics show promise for treating various mental disorders. We hope that, under the guidance of cognitive behavioral therapy, participants will benefit from this study and successfully reduce their cannabis usage.